P300 and treatment effect of modafinil on fatigue in multiple sclerosis

Journal of Clinical Neuroscience

Volumn 14, Issue 1, 2007, Pages 33-40

  Nagels, G ^a,b,c   D'hooghe, M B ^a   Vleugels, L ^a   Kos, D ^a,d   Despontin, M ^d   De Deyn, P P ^b,e,f  

^a National Multiple Sclerosis Center   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

^c ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^d FREE UNIVERSITY OF BRUSSELS   (Belgium)

^e MIDDELHEIM HOSPITAL   (Belgium)

^f Hogeschool Antwerpen   (Belgium)

Author keywords

Modafinil; Multiple sclerosis; P300; Prediction; Treatment effect

Indexed keywords

MODAFINIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; EVALUATION; FATIGUE; FEMALE; HEARING; HUMAN; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; TREATMENT OUTCOME; VISUAL ACUITY;

ACOUSTIC STIMULATION; ADULT; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; ELECTROENCEPHALOGRAPHY; ELECTROPHYSIOLOGY; EVENT-RELATED POTENTIALS, P300; FATIGUE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PHOTIC STIMULATION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 33751402462     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2005.10.008     Document Type: Article

References (13)

1. Branas P., Jordan R., Fry-Smith A., et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess 4 (2000) 1-61
2. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 54 (2000) 1166-1175
3. Broughton R.J., Fleming J.A., George C.F., et al. Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49 (1997) 444-451
4. Rammohan K.W., Rosenberg J.H., Lynn D.J., et al. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis: a two centre phase 2 study. J Neurol Neurosurg Psychiatry 72 (2002) 179-183
5. Zifko U.A., Rupp M., Schwarz S., et al. Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249 (2002) 983-987
6. Sangal R.B., Sangal J.M., and Belisle C. Visual P300 latency predicts treatment response to modafinil in patients with narcolepsy. Clin Neurophysiol 110 (1999) 1041-1047
7. Comi G., Martinelli V., Locatelli T., et al. Neurophysiological and cognitive markers of disease evolution in multiple sclerosis. Multiple Sclerosis 4 (1988) 260-265
8. Leocani L., and Comi G. Neurophysiological investigations in multiple sclerosis. Curr Opin Neurol 13 (2000) 255-261
9. Poser C.M., and Brinar V.V. Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg 106 (2004) 147-158
10. Piche T., Vanbiervliet G., Cherikh F., et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut 54 (2005) 1169-1173
11. Giesser B.S., Schroeder M.M., LaRocca N.G., et al. Endogenous event-related potentials as indices of dementia in multiple sclerosis patients. Electroencephalogr Clin Neurophysiol 82 (1992) 320-329
12. Schwid S.R., Thornton C.A., Pandya S., et al. Quantitative assessment of motor fatigue and strength in MS. Neurology 53 (1999) 743-750
13. Aminoff J.C., and Goodin D.S. Long-latency cerebral event-related potentials in multiple sclerosis. J Clin Neurophysiol 18 (2001) 372-377